FDA actions

Elliott, William T.
November 2008
Travel Medicine Advisor;Nov2008 Pharmacology Watch, p2
The article deals with the warning letters issued by the U.S. Food and Drug Administration in November 2008 to Ranbaxy Laboratories of India. The letters raised concerns about deviations from U.S. Good Manufacturing Practice requirements at the company's manufacturing facilities. The drug portfolio of Ranbaxy is mentioned.


Related Articles

  • Import alert issued.  // Contemporary Pediatrics;Oct2008, Vol. 25 Issue 10, p19 

    The article announces that the U.S. Food & Drug Administration (FDA) has issued a 2008 import alert for generic drugs produced by Ranbaxy Laboratories Limited's Dewas and Paonta Sahib plants in India, as well as two warning letters to Ranbaxy. According to the FDA, it detected deficiencies in...

  • Import alert: Ranbaxy facilities.  // WHO Drug Information;2008, Vol. 22 Issue 3, p203 

    The article reports on the issuance of two warning letters to Ranbaxy Laboratories Ltd. from the US Food and Drug Administration (FDA). The effort has simultaneously established an Import Alert for drugs manufactured or using materials from two Ranbaxy facilities in India at Dewas or Paonta...

  • Ranbaxy stops API shipments from Toansa, Dewas plants.  // FRPT- Chemical Snapshot;3/ 9/2014, p15 

    The article reports that Indian drug company Ranbaxy Laboratories Ltd. has suspended the shipments of active pharmaceutical ingredients (API) coming from its production facilities in Toansa, Punjab and Dewas, Madhya Pradesh. It notes that Ranbaxy's shipments to the U.S. have been stopped...

  • Ranbaxy ANDAs to Be Withdrawn.  // BioWorld Today;8/22/2012, Vol. 23 Issue 163, p5 

    The article discusses the request of Ranbaxy Laboratories for the U.S. Food and Drug Administration (FDA) to withdraw the approval of its 27 abbreviated new drug applications (ANDA), which include dosages of cefaclor, cefprozil, and glimepiride.

  • U.S. Gives Nod to Ranbaxy for Lipitor.  // News India Times;12/09/2011, Vol. 42 Issue 49, p16 

    The article reports that the U.S. Food and Drug Administration (FDA) has given Ranbaxy Laboratories Ltd. an approval to launch the cholesterol-lowering drug Lipitor in the U.S.

  • Ranbaxy files consent decree.  // BioSpectrum;Mar2012, Vol. 10 Issue 3, p74 

    The article reports on the move of Ranbaxy Laboratories Ltd. to file a consent decree with the U.S. Food and Drug Administration (FDA) to further strengthen its procedures and policies.

  • Ranbaxy Laboratories obtains US FDA approval to market fenofibrate capsules.  // Express Pharma;10/01/2014, p1 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the Fenofibrate capsules of Indian pharmaceutical company Ranbaxy Laboratories Ltd. for primary hypercholesterolemia and mixed dyslipidemia, as well as severe hypertriglyceridemia.

  • FDA Takes Action Against Ranbaxy.  // Chain Drug Review;2/17/2014, Vol. 36 Issue 4, p50 

    The article reports that the U.S. Food and Drug Administration has banned Indian generic drug maker Ranbaxy Laboratories Ltd., from exporting active pharmaceutical ingredients (APIs) to the U.S. from its Toansa plant in Punjab, India, after discovering safety violations at the facility.

  • Ranbaxy Receives Approval to Launch Generic Lipitor.  // India -- West;12/23/2011, Vol. 37 Issue 5, pA39 

    The article reports that generic drug maker Ranbaxy Laboratories Ltd. has received approval from the U.S. Food and Drug Administration to sell the generic version of cholesterol lowering blockbuster drug Lipitor.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics